Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Comparison of Two Artificial Liver Support Treatments for Acute-on-Chronic Liver Failure

7 de noviembre de 2026 actualizado por: Shan Zhong, The Second Affiliated Hospital of Chongqing Medical University

A Multicenter, Prospective, Non-Inferiority Cohort Study of Plasma Exchange Combined With Double Plasma Molecular Adsorption System (PE+DPMAS) Versus Plasma Exchange Combined With Continuous Renal Replacement Therapy (PE+CRRT) in Patients With Acute-on-Chronic Liver Failure

This study compares two blood-filtering treatment approaches used in adults with acute-on-chronic liver failure, a sudden worsening of liver function in people with long-term liver disease.

Both approaches include plasma exchange, which removes and replaces the liquid part of the blood. One approach combines plasma exchange with a system that uses filters to remove certain substances from the blood. The other combines plasma exchange with continuous kidney support therapy, which helps remove waste and excess fluid.

The treating doctors and patients decide which treatment to use as part of routine care. The study does not assign treatment. The researchers will follow participants to find out how many are alive without a liver transplant 90 days after joining the study. They will also compare complications, blood test results, and safety outcomes. Participants may choose to join a separate part of the study that collects blood and stool samples.

Descripción general del estudio

Estado

Aún no reclutando

Descripción detallada

This multicenter, prospective, observational cohort study uses a noninferiority design to compare two artificial liver support strategies in adults with acute-on-chronic liver failure: plasma exchange plus double plasma molecular adsorption system (PE plus DPMAS) and plasma exchange plus continuous renal replacement therapy (PE plus CRRT).

The planned enrollment is 400 participants across two hospitals, with a target of 200 participants in each cohort. Treatment decisions are made in routine clinical practice by the treating clinicians in consultation with patients. Participants are grouped according to the treatment they receive. The study protocol does not assign treatment, and there is no randomization.

The primary outcome is 90-day transplant-free survival, measured from enrollment. The first occurrence of death from any cause or liver transplantation is counted as an event. An independent committee blinded to treatment group adjudicates the primary outcome events. The analysis will use propensity score matching to address measured differences between the two cohorts.

An optional exploratory substudy plans to enroll 120 consenting participants. Research blood samples will be used for peripheral blood mononuclear cell single-cell RNA sequencing and plasma-based omics analyses. Stool samples will be used to characterize the gut microbiome. Participants may decline the substudy and still participate in the main cohort.

Tipo de estudio

De observación

Inscripción (Estimado)

400

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Porcelana, 400010
        • The Second Affiliated Hospital of Chongqing Medical University
        • Contacto:
    • Zhejiang
      • Hangzhou, Zhejiang, Porcelana, 310023
        • Hangzhou Xixi Hospital
        • Contacto:
          • Rui Wu
          • Número de teléfono: +86 13655813566

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 80 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

The study population consists of adults aged 18 to 80 years with acute-on-chronic liver failure who are scheduled to receive artificial liver support for the first time at one of two participating hospitals in China. Eligible patients who provide written informed consent are enrolled prospectively. The two cohorts are defined by the treatment received in routine clinical care: plasma exchange plus double plasma molecular adsorption system (PE plus DPMAS) or plasma exchange plus continuous renal replacement therapy (PE plus CRRT). The study protocol does not assign treatment.

Descripción

Inclusion Criteria:

  • Age 18 to 80 years, inclusive, regardless of sex.
  • Meets the protocol-defined AARC diagnostic criteria for acute-on-chronic liver failure, including all of the following:
  • Underlying chronic liver disease, including compensated cirrhosis, decompensated cirrhosis, or noncirrhotic chronic liver disease.
  • Acute hepatic decompensation within 4 weeks, presenting as jaundice and/or ascites and/or hepatic encephalopathy.
  • Serum total bilirubin of at least 5 mg/dL (85 micromol/L), together with either prothrombin activity of 40% or less or an international normalized ratio (INR) of at least 1.5.
  • Scheduled to receive artificial liver support for the first time, using either plasma exchange plus double plasma molecular adsorption system (PE plus DPMAS) or plasma exchange plus continuous renal replacement therapy (PE plus CRRT).
  • Able to understand the study purpose and procedures, willing and able to comply with study requirements, and personally provides written informed consent.
  • For the optional exploratory substudy only: agrees to provide blood and stool samples. Declining sample collection does not affect eligibility for the main cohort.

Exclusion Criteria:

  • Primary liver cancer or another malignancy.
  • Human immunodeficiency virus (HIV) infection.
  • Expected death within 24 to 48 hours, as independently determined by two investigators. If the investigators disagree, this criterion alone does not exclude the patient.
  • Pregnancy or breastfeeding.
  • Another serious illness associated with a life expectancy of less than 6 months, as judged by the investigator.
  • Current participation in another interventional clinical study.
  • Temporary or persistent lack of capacity to provide informed consent.
  • Any other circumstance that, in the investigator's judgment, makes the patient unsuitable for enrollment.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
PE Plus DPMAS

Adults with acute-on-chronic liver failure who receive plasma exchange (PE) in combination with the double plasma molecular adsorption system (DPMAS) as part of routine clinical care. The study protocol does not assign treatment.

PE Plus CRRT

Adults with acute-on-chronic liver failure who receive plasma exchange (PE) in combination with continuous renal replacement therapy (CRRT) as part of routine clinical care. The study protocol does not assign treatment.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
90-Day Transplant-Free Survival
Periodo de tiempo: From enrollment through Day 90

The percentage of participants who are alive and have not undergone liver transplantation at Day 90 after enrollment. Death from any cause or liver transplantation is counted as an event, whichever occurs first.

From enrollment through Day 90

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
28-Day Transplant-Free Survival
Periodo de tiempo: From enrollment through Day 28

The percentage of participants who are alive and have not undergone liver transplantation at Day 28 after enrollment. Death from any cause or liver transplantation is counted as an event, whichever occurs first.

From enrollment through Day 28
Occurrence of Liver Transplantation
Periodo de tiempo: From enrollment through Day 90

The percentage of participants who undergo liver transplantation during follow-up. The date of transplantation is recorded.

From enrollment through Day 90
Change in Hepatic Encephalopathy Grade
Periodo de tiempo: Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment

Change in West Haven hepatic encephalopathy grade from baseline at each follow-up assessment, categorized as improvement, no change, or worsening.

Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
Reversal of Hepatorenal Syndrome
Periodo de tiempo: Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment

Percentage of participants with hepatorenal syndrome at baseline who meet the prespecified criteria for reversal at each follow-up assessment. Hepatorenal syndrome is diagnosed according to the International Club of Ascites criteria specified in the study protocol.

Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
Correction of Hyponatremia
Periodo de tiempo: Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment

Percentage of participants with hyponatremia at baseline who meet the prespecified correction criterion at each follow-up assessment, based on serum sodium measurements.

Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
Correction of Hyperkalemia
Periodo de tiempo: Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment

Percentage of participants with hyperkalemia at baseline who meet the prespecified correction criterion at each follow-up assessment, based on serum potassium measurements.

Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
Change From Baseline in SOFA Score
Periodo de tiempo: Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment

Change in the Sequential Organ Failure Assessment (SOFA) score from baseline at each follow-up assessment. The total score ranges from 0 to 24, with higher scores indicating more severe organ dysfunction.

Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
Relative Change in Total Bilirubin From Baseline During Serial Treatment and Follow-up
Periodo de tiempo: Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment

elative change in total bilirubin from baseline at each subsequent treatment-related and follow-up assessment, using the prespecified calculation method. Treatment-related measurements are obtained within 48 hours before the start and within 48 hours after the end of each artificial liver support session. Both increases and decreases are recorded.

Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment
Change in Blood Ammonia From Baseline
Periodo de tiempo: Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment

Change in blood ammonia concentration from baseline at each postbaseline assessment, reported in micromoles per liter (μmol/L). Measurements are obtained within 48 hours before the start and within 48 hours after the end of each artificial liver support session, and at the scheduled follow-up assessments.

Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment
Change in Serum Creatinine From Baseline
Periodo de tiempo: Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment

Change in serum creatinine concentration from baseline at each postbaseline assessment, reported in micromoles per liter (μmol/L). Measurements are obtained within 48 hours before the start and within 48 hours after the end of each artificial liver support session, and at the scheduled follow-up assessments.

Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment
Change in INR From Baseline
Periodo de tiempo: Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment

Change in the international normalized ratio (INR) from baseline at each postbaseline assessment. Measurements are obtained within 48 hours before the start and within 48 hours after the end of each artificial liver support session, and at the scheduled follow-up assessments.

Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

16 de noviembre de 2026

Finalización primaria (Estimado)

30 de junio de 2028

Finalización del estudio (Estimado)

30 de septiembre de 2028

Fechas de registro del estudio

Enviado por primera vez

3 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

7 de noviembre de 2026

Publicado por primera vez (Actual)

12 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

7 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

There is no plan to share individual participant data with researchers outside the study team. Aggregate results may be reported in publications.

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir